Article Figures & Data
Figures
- Figure 1.
Cardiovascular screening and statin therapy in breast cancer (BC) survivors. A, BC survivors are more likely to have received cholesterol screening and statin therapy than matched controls. B, Subgroup analysis of BC survivors with a diagnosis of hypertension have no differences in blood pressure control compared with comorbidity matched peers. C, Subgroup analysis of BC survivors are more likely than matched controls to have an active statin prescription if indicated. Sample size is indicated in parentheses for each group. Abbreviation: BMI, body mass index. *P < .05, ** P < .01, ***P < .001.
- Figure 2.
Cardiovascular screening, management, and comorbidities in African American and White breast cancer (BC) survivors. A, No differences in cardiovascular screening and management were observed between White and African American BC survivors; however, African American BC survivors were found to have a decreased incidence of having a body mass index less than 25 kg/m2. B, African American BC survivors are more likely to have a diagnosis of hypertension. Sample size is indicated in parentheses for each group. Abbreviation: BMI, body mass index. *P < .05, ***P < .001.
- Figure 3.
Impact of age on cardiovascular screening breast cancer (BC) survivors. A, Cardiovascular screening and management of BC survivors stratified by age. Older individuals are more likely to have received cholesterol screening than younger counterparts. B, Incidence of comorbidities based on age in BC survivors. Older BC survivors have a higher incidence of hypertension. Sample size is indicated in parentheses for each group. *P < .05, **P < .01, ***P < .001.
Tables
BC Survivors Matched Control Age, mean (SD) 63 (8.5) 63 (8.5) Individuals, n 105 210 Ethnicity White 48% (51) 57% (120) African American 44% (46) 39% (82) Hispanic or Latino 4% (4) 1% (2) Asian 4% (4) 3% (6) Medical comorbidities Hypertension 63% (66) 63% (132) Hyperlipidemia 32% (34) 34% (73) Diabetes 27% (28) 29% (61) Cardiotoxic therapies received None 25% (26) One or more 77% (81) Two or more 42% (44) Cancer therapy Radiation therapy 38% (40) Chemotherapy 38% (40) Endocrine therapy 55% (58) Stage at diagnosis 0 16% (17) 1 36% (38) 2 22% (23) 3 4% (4) 4 2% (2) Unknown 20% (21) Cardiovascular metrics ASCVD risk 10.9% (8.6) 11.9% (8.1) Body mass index 30.4 (7.6) 30.9 (9.9) Major cardiovascular events 6.7% (7) 1.4% (3) Hemoglobin A1c <9% (n = 89) 67.2% (20) 71.4% (41) Lipid screening by primary care 93.7% (90) 88.3% (129) Statin therapy by primary care 93.6% (44) 87.7% (50) ASCVD, atherosclerotic cardiovascular disease; BC, breast cancer, SD, standard deviation.
Cancer survivors seen within 3 months were matched with controls based on age and medical comorbidity of hypertension, hyperlipidemia, and diabetes mellitus.
In this issue
